Logo

PCSC

Perceptive Capital Solutions Corp Class A Ordinary Shares

PCSC

Perceptive Capital Solutions Corp Class A Ordinary Shares • NASDAQ
$10.79 ▲ 0.37% (+0.04)
Market Cap $119.42 M
52w High $10.79
52w Low $10.13
Dividend Yield 0%
P/E 0
Volume 137
Outstanding Shares 11.07M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $856.16K ▲ $144.634K ▼ 0% $0.01 ▼ $144.634K ▲
Q2-2025 $0 $193.196K ▼ $754.847K ▲ 0% $0.068 ▲ $-193.196K ▲
Q1-2025 $0 $255.958K ▲ $678.555K ▼ 0% $0.061 ▼ $-255.958K ▼
Q4-2024 $0 $175.926K ▼ $841.432K ▼ 0% $0.12 ▲ $-175.926K ▲
Q3-2024 $0 $196.128K $981.482K 0% $0.089 $-196.128K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.178M ▼ $92.201M ▲ $4.385M ▲ $87.816M ▲
Q2-2025 $1.344M ▲ $91.403M ▲ $3.731M ▲ $87.672M ▲
Q1-2025 $1.192M ▲ $90.632M ▲ $3.716M ▼ $86.917M ▲
Q4-2024 $1.13M ▼ $89.899M ▲ $92.015M ▲ $-2.116M ▼
Q3-2024 $1.209M $89.007M $3.61M $85.397M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $144.634K ▼ $-166.5K ▼ $0 ▼ $0 $-166.5K ▼ $-166.5K ▼
Q2-2025 $754.847K ▲ $-147.528K ▲ $300K $0 $152.472K ▲ $-147.528K ▲
Q1-2025 $678.555K ▼ $-237.747K ▲ $300K ▲ $0 ▼ $62.253K ▲ $-237.747K ▲
Q4-2024 $841.432K ▼ $-439.406K ▼ $0 $359.637K ▲ $-79.769K ▼ $-439.41K ▼
Q3-2024 $981.482K $-77.528K $0 $0 $-77.528K $-77.528K

Five-Year Company Overview

Income Statement

Income Statement PCSC is a newly listed SPAC, so its income statement is essentially empty from an operating perspective. It has no revenue, no ongoing business activities, and no real profits or losses from selling products or services. Any reported earnings mainly reflect accounting effects from the IPO structure and interest on cash, not a running business. The financial story here will only really begin once it announces and completes a merger with an operating company.

Balance Sheet

Balance Sheet The balance sheet is very simple: PCSC mainly holds cash and shareholder equity from the funds raised in its IPO, with no meaningful operating assets and no traditional business liabilities. There is essentially no debt and no complex financing yet. Think of it as a pool of capital in a listed shell, waiting to be deployed into a future acquisition rather than a company with factories, intellectual property, or operating subsidiaries already in place.

Cash Flow

Cash Flow Cash flows are minimal and mostly administrative at this stage. There is no cash coming in from customers and no cash outlay for production, marketing, or research. Most movements in cash are tied to the IPO itself, the trust account, and routine corporate expenses. The real cash flow profile will only emerge once a merger target is announced and combined, so current cash figures mostly tell you the size of the war chest, not the health of an operating business.

Competitive Edge

Competitive Edge As a SPAC, PCSC’s competitive position is about deal-making rather than day‑to‑day competition in a product market. Its main edge is the reputation and network of Perceptive Advisors in healthcare and life sciences. This can help it source attractive private companies that may not be easily accessible to other SPACs or traditional investors. However, it is also one of many SPACs chasing a limited pool of qualified targets, so there is real competition to find and secure a compelling deal on reasonable terms.

Innovation and R&D

Innovation and R&D PCSC itself does not develop products, run laboratories, or fund internal R&D. Its “innovation” angle is entirely indirect: it aims to merge with a healthcare or life sciences company that already has strong scientific or technological advantages. In that sense, the real innovation and research story will belong to whichever company PCSC eventually acquires. Until that target is identified and disclosed, there is no meaningful R&D profile to analyze for PCSC on a standalone basis.

Summary

PCSC is a blank-check company: a clean financial shell holding capital and backed by an experienced healthcare-focused sponsor. Today, its statements show almost no operating activity, no revenue, and a straightforward cash-heavy balance sheet with little complexity. The key driver of future value will be management’s ability to identify, negotiate, and close a merger with a high‑quality healthcare or life sciences business. Until that happens, analysis is mostly about structure, governance, and sponsor reputation rather than traditional financial performance or business fundamentals.